PT  - JOURNAL ARTICLE
AU  - Blair, David R.
AU  - Risch, Neil
TI  - Dissecting the Reduced Penetrance of Putative Loss-of-Function Variants in Population-Scale Biobanks
AID  - 10.1101/2024.09.23.24314008
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.23.24314008
4099  - http://medrxiv.org/content/early/2024/10/07/2024.09.23.24314008.short
4100  - http://medrxiv.org/content/early/2024/10/07/2024.09.23.24314008.full
AB  - Loss-of-function variants (LoFs) disrupt the activity of their impacted gene. They are often associated with clinical phenotypes, including autosomal dominant diseases driven by haploinsufficiency. Recent analyses using biobanks have suggested that LoF penetrance for some haploinsufficient disorders may be low, an observation that has important implications for population genomic screening. However, biobanks are also rife with missing data, and the reliability of these findings remains uncertain. Here, we examine the penetrance of putative LoFs (pLoFs) using a cohort of ≈24,000 carriers derived from two population-scale biobanks: the UK Biobank and the All of Us Research Program. We investigate several possible etiologies for reduced pLoF penetrance, including biobank recruitment biases, annotation artifacts, missed diagnoses, and incomplete clinical records. Systematically accounting for these factors increased penetrance, but widespread reduced penetrance remained. Therefore, we hypothesized that other factors must be driving this phenomenon. To test this, we trained machine learning models to identify pLoFs with high penetrance using the genomic features specific to each variant. These models were predictive of penetrance across a range of diseases and pLoF types, including those with prior evidence for pathogenicity. This suggests that reduced pLoF penetrance is in fact common, and care should be taken when counseling asymptomatic carriers.Competing Interest StatementThe first author (D. Blair) has received research funding from BioMarin, Idorsia, QED Therapeutics and Sanofi in the last 36 months. None of the research reported in this manuscript was funded by these entities.Funding StatementThis work was supported by grants from the National, Heart, Lung and Blood Institute (K38HL164956) and the George Banks and Sarah Ellen Huntington Memorial Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB). Approved researchers do not require separate ethical clearance and can operate under the RTB approval. The UKBB was accessed via approved Application Number 99922. Authorization for access to participant-level data in All of Us is based on a "data passport" model, through which authorized researchers do not need IRB review for each research project. The data passport is required for gaining data access to the Researcher Workbench and for creating workspaces to carry out research projects using All of Us data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe genomic and electronic health data used for this analysis are publicly available but have data use agreements. The process for obtaining access to these biobanks can be found on their respective websites: https://www.researchallofus.org/register/ (All of Us Research Program) and https://www.ukbiobank.ac.uk/enable-your-research/register (UK Biobank). Haploinsufficient disease annotations are provided in Supplemental Table 1. The custom HPO-to-OMOP concept alignments generated in this study are provided as Supplemental Table 10. All other databases used in this analysis are freely available in the public domain.